Skip to content

MoonLake Immunotherapeutics

MLTX

CIK 0001821586 · Pharmaceutical Preparations · Nasdaq

  • Helix Acquisition Corp (until 2022-03-31)
← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$234.6M
−91.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$3.58
−86.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$128.65M
Q1 May 2026
Cash
$298.49M
Q1 May 2026
Total Debt
$99.02M
Q1 May 2026
Shares Outstanding
73.62M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings